iRhythm Holdings stock barely flinched after earnings, slipping just 0.2% to about US$127. That muted move sits awkwardly next to a quarter that effectively erased the company’s losses and pushed free cash flow firmly into positive territory. This is a classic sentiment mismatch, where a cardiology technology business posts record adjusted profitability while the share price trades as if very little has changed.

The real headline is simple. iRhythm just paired roughly US$224.2m in revenue with record adjusted EBITDA margin and positive free cash flow, yet the market reaction stayed almost flat.

Love iRhythm Holdings’ shift to positive free cash flow but want more stocks that pair healthy margins with solid balance sheets? Check out our curated screener of list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs. Q2 2025: US$224.2m vs. US$186.7m (around 20% higher year over year)
• Net Income/Loss Q2 2026 vs. Q2 2025: Net loss of US$0.4m vs. net loss of US$14.2m (loss significantly reduced year over year)
• Basic EPS Q2 2026 vs. Q2 2025: loss of US$0.01 per share vs. loss of US$0.44 per share (per share loss significantly reduced year over year)
• Adjusted EBITDA Margin Q2 2026 vs. Q2 2025: 19.3%, with the prior year level not specified (record margin performance for iRhythm Holdings)

Prefer clean charts over squinting at another wall of earnings tables and footnotes? Get a full visual view of iRhythm Holdings, with an at a glance breakdown of its recent profitability trend in our company report for iRhythm Holdings.

iRhythm Bull Case Meets Key Profitability Milestones

Bulls argue that iRhythm can pair sustained mid‑teens or better revenue growth with a step change in profitability as Zio scales and AI takes out cost. Q2 moves this from theory to evidence. Revenue reached US$224.2m with the company now logging a seventh straight quarter above 20% growth, which lines up with the growth profile bulls have highlighted.

The more important proof point is earnings quality. Gross margin of 72.8%, record 19.3% adjusted EBITDA margin, largely flat adjusted operating expenses and US$37.5m of free cash flow show that higher volumes are not being bought with heavier spending. Guidance raises for both 2026 revenue and full year adjusted EBITDA margin, plus the plan to keep gross margin above 70% after adding Vital Connect, all support the idea that iRhythm’s scale and AI driven workflows are starting to deliver the margin story bulls have been looking for.

Track how iRhythm Holdings’ margin story and free cash flow shift lines up against institutional expectations by checking whether analysts are raising or cutting their targets. Compare that operational progress with the street’s stance in the consensus price target analysis for iRhythm Holdings.

Bears Still See iRhythm Growth Story As Fragile

The harshest take on iRhythm Holdings is that growth beyond cardiology is fragile and tied to slow moving primary care workflows, heavy EHR integration and a still unproven AI layer. Q2 volume was led by cardiology and “innovative channels,” with no concrete metrics on primary care penetration or EHR driven study volumes. That leaves the concern about channel dependence largely intact.

Bears also worry that mobile cardiac telemetry, or MCT, timing risk keeps margin gains temporary. The next generation Zio MCT is still targeted for FDA clearance in 2027 and Vital Connect will not contribute until at least 2027. That pushes out the point where the broader MCT and multi vital story can be judged. Finally, international and adjacent markets such as sleep and hospital to home remain pipeline comments rather than quantified revenue, so the warning about stretched growth expectations outside the core US Zio franchise is not disproved yet.

After delays to Zio MCT and limited disclosure on primary care traction, it is fair to ask whether iRhythm Holdings has other structural weak spots that are harder to see from headline margins alone. Review the independent risk analysis for iRhythm Holdings which shows 1 important warning sign

Stay Ahead With Simply Wall St

If the gap between iRhythm Holdings’ stronger margins and the flat share price has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. Once you own iRhythm Holdings or other stocks, keep your decisions clear with the Portfolio Command Center that highlights only the most important updates on your holdings. For a broader view on what other investors are thinking, tap into the Community and see different perspectives before your next move. By spotting hidden catalysts and potential risks early, you give yourself a better chance to stay ahead of the market rather than reacting to it late.

Seeking Fresh Alternatives Beyond iRhythm

New stock stories can move from quiet to breakout fast. Spot fresh momentum while it matters and before they get fully priced by everyone else. Get in early.

• Hunt for under the radar cash generators using the curated 19 high quality undiscovered gems that pair solid fundamentals with stories the wider market has not fully caught yet.
• Ride steady income streams by scanning the hand picked 8 dividend fortresses that aim to combine robust payouts with balance sheets built to handle more than just fair weather.
• Target potential growth plus financial strength by filtering through the curated list of solid balance sheet and fundamentals stocks (49 results) that focus on quality companies with room for fresh momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.